CJC-1295 with DAC: Research Overview

Palmetto Peptides Research Team

February 22, 2026

cjc-1295growth-hormonepeptidesresearch

CJC-1295 with DAC is a modified growth hormone-releasing hormone (GHRH) analog that incorporates a Drug Affinity Complex (DAC) technology — a maleimidoproprionic acid (MPA) reactive group that covalently binds to circulating serum albumin. This bioconjugation dramatically extends the compound's plasma half-life to 5–7 days, enabling sustained, continuous stimulation of the pituitary somatotroph cells. It represents a fundamentally different research tool from its shorter-acting counterpart, CJC-1295 Without DAC.

Molecular Design and DAC Technology

The foundational GHRH sequence used in CJC-1295 is the same modified 29-amino acid peptide (Mod GRF 1-29) that confers DPP-IV resistance via four amino acid substitutions. The critical addition in the "with DAC" variant is a reactive lysine side chain at the C-terminus that carries the MPA moiety.

Albumin Bioconjugation Mechanism

Upon administration, the MPA group reacts with a free cysteine residue on serum albumin (Cys-34) via a Michael addition reaction, forming a stable thioether bond. Because albumin has a half-life of approximately 19 days in circulation, the conjugated peptide persists in plasma far longer than unconjugated GHRH analogs. The GHRH peptide remains biologically active while albumin-bound, as the binding occurs at the peptide's C-terminus away from the receptor-binding N-terminal domain.

This technology was pioneered by ConjuChem Biotechnologies and represents a platform applicable to many short-lived peptide therapeutics. CJC-1295 with DAC was among the first GHRH analogs to reach clinical trials using this approach.

Pharmacokinetics: Continuous vs. Pulsatile GH Release

The most significant research distinction between CJC-1295 with and without DAC lies in the resulting GH secretion pattern:

Pulsatile (Without DAC): GH rises sharply 15–30 minutes post-administration and returns to baseline within 2–3 hours, mimicking physiological GH pulse dynamics.
Continuous (With DAC): Once-weekly or biweekly administration maintains elevated, relatively constant GH/IGF-1 levels. Research by Jetté et al. (2005) demonstrated that CJC-1295 with DAC produced dose-dependent increases in mean GH concentrations lasting 6–8 days per injection in healthy adult subjects.

Neither pattern is inherently superior for all research applications — the appropriate choice depends on the biological question under investigation.

Key Research Studies

Clinical Pharmacokinetics

The landmark clinical study of CJC-1295 with DAC (Jetté et al., 2005, published in the Journal of Clinical Endocrinology & Metabolism) enrolled 65 healthy adults aged 21–61 years. Results demonstrated:

Mean GH levels increased 2–10 fold above baseline depending on dose
IGF-1 levels increased 1.5–3 fold above baseline
Effects persisted for 6–8 days after a single injection
No significant adverse effects were observed at study doses

This study established critical pharmacokinetic parameters that have guided subsequent preclinical research using CJC-1295 with DAC.

Body Composition Research

Preclinical studies in rodent models examining chronic GHRH analog administration have reported significant effects on body composition, including increased lean mass and reduced adiposity. Research in aged rats demonstrated reversal of age-related somatotropic axis decline, with sustained IGF-1 elevation correlating with improved body composition metrics. These findings have informed mechanistic hypotheses about somatopause and potential interventional research directions.

Research Protocols

CJC-1295 with DAC is reconstituted as a lyophilized peptide in bacteriostatic water prior to use. The extended half-life means research protocols typically examine once-weekly or biweekly administration schedules. Reconstituted peptide should be stored at 2–8°C and used within 28 days. The covalent albumin binding that occurs in vivo makes in vitro reconstituted solutions behave differently from in vivo administration — a consideration relevant to cell culture studies.

When designing research protocols, investigators should allow 4–6 weeks for IGF-1 levels to reach steady state before assessing chronic effects. This contrasts with Mod GRF 1-29 studies where each administration produces an acute, self-limiting GH pulse.

Research Comparison: DAC vs. Without DAC

Choosing between the two variants requires careful consideration of study objectives:

Pulsatile GH research: Mod GRF 1-29 is preferred when studying GH pulse dynamics, receptor desensitization kinetics, or acute GH-mediated signaling events.
Chronic elevation studies: CJC-1295 with DAC is preferred when studying IGF-1-mediated anabolic effects over extended timeframes or when modeling pathological states of continuous GH excess.
Receptor downregulation: Research has shown that continuous GHRH receptor stimulation can lead to receptor desensitization — an important variable in long-term studies.

Frequently Asked Questions

How does albumin binding preserve the peptide's activity?

The MPA DAC moiety binds to albumin's Cys-34 residue via a stable thioether bond. The GHRH peptide sequence occupies a position away from the albumin binding site, allowing it to remain accessible to pituitary GHRH receptors. The albumin complex also protects the peptide from proteolytic degradation and renal clearance.

What does CJC-1295 with DAC research tell us about GH replacement strategies?

The clinical data established that once-weekly GHRH analog administration can maintain physiologically meaningful GH and IGF-1 elevation, providing a research model for understanding how continuous vs. pulsatile GH delivery affects tissue responses differently.

Can CJC-1295 with DAC be combined with GHRPs?

Research protocols have examined GHRH/GHRP combinations using both variants. Because CJC-1295 with DAC provides background GHRH tone, adding a GHRP like Ipamorelin still produces GH pulse amplification above the already-elevated baseline, though the pulsatile response characteristics differ from those observed with Mod GRF 1-29.

References

Jetté L, et al. (2005). hGRF1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. PMID: 16002529
Teichman SL, et al. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism. PMID: 16636129
Frohman LA, Jansson JO. (1986). Growth hormone-releasing hormone. Endocrine Reviews. PMID: 2874980

Disclaimer: All compounds offered by Palmetto Peptides are strictly for laboratory research and in vitro studies. They are not intended for human consumption, veterinary use, or any therapeutic application. All information provided is for educational and scientific reference only. Palmetto Peptides makes no health claims. Consult a licensed medical professional before handling any research compound.